8-K: Fortress Biotech Secures $35 Million Loan, Refinances Existing Debt

Fortress Biotech has entered into a new $35 million loan agreement with Oaktree, replacing its previous $50 million loan and extending its debt maturity to 2027.

Summary

• Fortress Biotech has secured a new $35 million loan from Oaktree, with an option to draw an additional $15 million.
• This new loan replaces a previous $50 million loan, which has been fully repaid.
• The new loan has a 30-month interest-only period and matures in July 2027.
• The interest rate is based on the 3-month SOFR plus 7.625%, with a floor of 2.50% and a cap of 5.75%.
• The company is required to make quarterly interest-only payments.
• 50% of the principal is due on March 31, 2027, with the remainder due at maturity.
• The company must make mandatory prepayments from certain events, including asset sales and excess subsidiary distributions.
• Lenders may receive warrants instead of cash for some mandatory prepayments.
• The agreement includes financial covenants, such as maintaining a minimum liquidity of $7.0 million and Journey Medical Corporation achieving $50.0 million in trailing 12-month net sales.
• The company is also required to raise at least $20 million in equity or monetizations annually.
• The company has granted warrants to the lenders to purchase up to 506,390 shares of common stock at $2.0735 per share.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company has secured new financing, extended its debt maturity, and has a promising pipeline. However, the financial covenants and mandatory prepayment terms introduce some risk.

Positives

• The new loan extends the maturity of the company's debt to July 2027, providing more financial flexibility.
• The company has the potential to draw an additional $15 million, supporting future business development.
• The interest-only period for 30 months reduces immediate cash flow pressure.
• The company has a strong pipeline with potential for multiple regulatory approvals in the near term.
• The company has a strategic partnership with Oaktree, a leading provider of debt financing in the life sciences industry.

Negatives

• The loan agreement includes financial covenants that the company must meet, including minimum liquidity and sales targets for Journey Medical Corporation.
• The company is required to raise at least $20 million in equity or monetizations annually.
• The loan is secured by substantially all of the company's assets.
• The company is subject to mandatory prepayments under certain conditions.
• The interest rate is variable and subject to market fluctuations.

Risks

• Failure to meet financial covenants could result in an event of default.
• The company's ability to raise the required equity or monetizations annually is uncertain.
• The company's reliance on a single lender for a significant portion of its debt could pose a risk.
• The variable interest rate exposes the company to potential increases in borrowing costs.
• The company's pipeline is subject to regulatory risks and uncertainties.

Future Outlook

The company expects the new loan agreement to provide financial flexibility for long-term expansion, including sourcing and acquiring assets, and executing on its existing commercial business and late-stage pipeline. They anticipate up to three regulatory approvals in the next 12 months and potentially a fourth BLA filing as early as 2025.

Management Comments

• Lindsay A. Rosenwald, M.D., Fortress Chairman, President and Chief Executive Officer, said, 'Oaktree has been a great partner to us and we are very pleased to continue to collaborate with them.'
• Lindsay A. Rosenwald, M.D., also stated, 'This arrangement allows us to fully repay our prior $50 million principal balance that was due in August 2025 and improves our capital flexibility with a maturity date on the new loan of July 2027.'
• Aman Kumar, Co-Portfolio Manager for Oaktrees Life Sciences Lending platform, commented, 'We are delighted to continue our strategic partnership with Fortress, supporting their ability to source, acquire and develop innovative assets with strong proof-of-concept in humans and the potential to address areas of high unmet medical need.'

Industry Context

This announcement reflects a common practice in the biopharmaceutical industry where companies utilize debt financing to fund operations and acquisitions. Oaktree's significant investment in the life sciences sector highlights the ongoing interest in this space. The refinancing of debt is a strategic move to improve financial flexibility and extend the runway for growth.

Comparison to Industry Standards

• The interest rate of SOFR plus 7.625% is within the typical range for secured loans in the biotech sector, although the floor and cap provide some protection against interest rate volatility.
• The requirement for minimum liquidity and sales targets is a standard practice in loan agreements to protect lenders.
• The issuance of warrants to lenders is a common practice in the biotech industry, providing lenders with potential upside in the company's stock.
• Companies like Biohaven Pharmaceutical and Amarin Corporation have also utilized debt financing to support their operations and acquisitions, demonstrating the prevalence of this strategy in the industry.
• The size of the loan, $35 million, is relatively modest compared to some larger biotech financings, but is appropriate for a company of Fortress Biotech's size and stage.

Stakeholder Impact

• Shareholders will benefit from the extended debt maturity and potential for growth.
• Employees will have more job security due to the improved financial stability.
• Customers will benefit from the continued development and commercialization of new products.
• Suppliers will have more confidence in the company's ability to pay its obligations.
• Creditors will have a secured interest in the company's assets.

Next Steps

• The company will file a Form 8-K with the SEC providing further details on the loan agreement.
• The company will need to meet the financial covenants outlined in the loan agreement.
• The company will need to execute on its pipeline and commercialization plans to generate revenue and meet the sales targets for Journey Medical Corporation.
• The company will need to raise at least $20 million in equity or monetizations annually.

Key Dates

Keywords

Fortress Biotech, Oaktree, Loan Agreement, Debt Financing, Biopharmaceutical, Warrants, Regulatory Approvals, Financial Covenants, SOFR, Journey Medical Corporation